Emmaus enters Exclusive Supply Agreement with NeoImmuneTech for Endari in US/Canada

Emmaus Life Sciences, Inc.

Agreement dated March 2, 2026; Emmaus to supply Endari (L-glutamine) exclusively to NIT for sickle cell disease in US and Canada.
Supply price is Emmaus' production cost plus a specified double-digit percentage margin.
Effective Date contingent on NIT obtaining necessary regulatory approvals and licensing; must occur by October 1, 2026.
Either party may terminate if Effective Date does not occur by Oct 1, 2026 (unless due to Emmaus' wrongful acts).
Exclusive Supply Agreement is a follow-up to the License Agreement reported on December 31, 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Emmaus Life Sciences, Inc. entered into Exclusive Supply Agreement with NeoImmuneTech, Inc. (NIT) (effective 2026-03-02).

Action: entry
Agreement: supply
Counterparty: NeoImmuneTech, Inc. (NIT)
Effective: 2026-03-02

Exact text from the filing

n March 2, 2026, Emmaus and NIT entered into the Exclusive Supply Agreement contemplated by the License Agreement. Subject to the occurrence

View on SEC.gov

Browse all material agreements →

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-023644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.